Upgrade to SI Premium - Free Trial

Pfizer (PFE) Phase 3 Trial of Revatio in Newborns with PPHN Did Not Meet its Primary Efficacy Endpoint

June 28, 2019 4:06 PM
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot FDA News

Next Articles